High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomi… (NCT07566650) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS) for Hypertension: A Randomized Controlled Trial
China50 participantsStarted 2026-05-01
Plain-language summary
This study focuses on individuals with primary hypertension, with the main objective of investigating the effectiveness and safety of high-intensity transcranial alternating current stimulation (Hi-tACS) as a non-invasive, non-pharmacological treatment for hypertension
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Clinical diagnosis of primary hypertension (Grade 1-3) as defined by the Chinese Hypertension Guidelines (Revised Edition 2024).
* For females of childbearing potential, agreement to use contraception during the study.
* Willing and able to comply with study procedures and provide written informed consent.
Exclusion Criteria:
* Women who are pregnant, breastfeeding, or planning pregnancy during the study period.
* Resistant hypertension (blood pressure uncontrolled despite adherence to ≥3 antihypertensive drugs of different classes at optimal doses, including a diuretic ), or known secondary hypertension.
* History of severe cardiovascular or cerebrovascular disease (e.g., myocardial infarction, stroke, heart failure NYHA Class III-IV) within the past 6 months, or severe hepatic or renal dysfunction (defined as ALT/AST \>3× upper limit of normal \[ULN\], or eGFR \<30 mL/min/1.73 m²).
* Uncontrolled sleep apnea syndrome, active infectious diseases, chronic wasting diseases, or significant cognitive impairment.
* Current major psychiatric disorder as assessed by the Mini-International Neuropsychiatric Interview (M.I.N.I.).
* Contraindications to tACS or MRI: implanted electronic devices, intracranial metal implants, or known history of seizures.
* Skin lesions, eczema, or broken skin at the intended electrode placement sites.
* Participation in another clinical trial involving an investigational product or device within 30 days prior to screening.
* Any…
What they're measuring
1
Difference in systolic blood pressure at end of treatment
Timeframe: From baseline to week 4 (end of treatment)